Literature DB >> 16112043

Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis.

Abraham Rutgers1, Marjan Slot, Pieter van Paassen, Peter van Breda Vriesman, Peter Heeringa, Jan Willem Cohen Tervaert.   

Abstract

BACKGROUND: In a substantial proportion of patients with crescentic glomerulonephritis (CGN), both anti-glomerular basement membrane (GBM) antibodies and antineutrophil cytoplasmic antibodies (ANCAs) with specificity for myeloperoxidase (MPO-ANCA) are detected. In the present study, we questioned whether histological and clinical features of patients with both ANCA and anti-GBM antibodies differ from those of patients with either ANCA or anti-GBM alone.
METHODS: We reviewed the Limburg renal biopsy registry (1978 to 2003; n = 1,373) for cases of CGN. The presence of linear fluorescence on renal biopsy and the presence of ANCA and/or anti-GBM antibodies were measured. Subsequently, we assessed patient characteristics and follow-up and compared histological findings among the different groups.
RESULTS: We identified 46 MPO-ANCA-positive, 10 double-positive, and 13 anti-GBM-positive patients. Mean ages were 63, 64, and 52 years (P = 0.04), and serum creatinine levels were 5.0, 10.3, and 9.6 mg/dL (445, 910, and 850 micromol/L), respectively (P = 0.01). Granulomatous periglomerular inflammation was found in either MPO-ANCA- or double-positive patients, but not in anti-GBM-positive patients with CGN without MPO-ANCAs. Patient survival among the 3 groups was different, although not statistically significant (log rank P = 0.17, with 75%, 79%, and 100% alive at 1 year, respectively). Renal survival analysis showed significant differences among the 3 groups (P = 0.04, with 65%, 10%, and 15% off dialysis therapy at 1 year, respectively).
CONCLUSION: In patients with both anti-GBM antibodies and MPO-ANCAs, histological findings differ from those of patients with anti-GBM antibodies only. However, renal survival in these patients is not better than that in anti-GBM-positive patients and is worse compared with patients with MPO-ANCAs only.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16112043     DOI: 10.1053/j.ajkd.2005.05.003

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  50 in total

1.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

2.  Propylthiouracil-associated rapidly progressive crescentic glomerulonephritis with double positive anti-glomerular basement membrane and antineutrophil cytoplasmic antibody: the first case report.

Authors:  Pitchaporn Kantachuvesiri; Panas Chalermsanyakorn; Bunyong Phakdeekitcharoen; Thitima Lothuvachai; Kannika Niticharoenpong; Piyanuch Radinahamed; Neil Turner; Surasak Kantachuvesiri
Journal:  CEN Case Rep       Date:  2014-12-31

3.  AP-VAS 2012 case report: anti-glomerular basement membrane disease with high titer of myeloperoxidase anti-neutrophil cytoplasmic antibody-an autopsy case report.

Authors:  Miho Otani; Hiroki Shoji; Hiromi Tomioka; Toshihiko Kaneda; Yoko Kida; Masahiro Kaneko; Hiroshi Fujii; Yoshihiko Nakajima; Eiji Katsuyama
Journal:  CEN Case Rep       Date:  2013-04-10

4.  Renal-limited vasculitis with elevated levels of multiple antibodies.

Authors:  Noriaki Sato; Hideki Yokoi; Hirotaka Imamaki; Eiichiro Uchino; Kaoru Sakai; Takeshi Matsubara; Tatsuo Tsukamoto; Sachiko Minamiguchi; Motoko Yanagita
Journal:  CEN Case Rep       Date:  2017-03-03

5.  A case of PR3-ANCA-positive anti-GBM disease associated with intrarenal arteritis and thrombotic microangiopathy.

Authors:  Shun Manabe; Mayuko Banno; Marie Nakano; Teruhiro Fujii; Yukio Kakuta; Kosaku Nitta; Michiyasu Hatano
Journal:  CEN Case Rep       Date:  2016-10-31

6.  Combined membranous nephropathy and crescentic glomerulonephritis with concurrent anti-glomerular basement membrane antibody and myeloperoxidase-specific anti-neutrophil cytoplasmic antibody.

Authors:  Yoichi Iwafuchi; Takashi Morita; Yuko Oyama; Akira Kamimura; Shigeru Miyazaki; Ichiei Narita
Journal:  CEN Case Rep       Date:  2013-01-30

7.  Thrombotic thrombocytopenic purpura in a patient with rapidly progressive glomerulonephritis with both anti-glomerular basement membrane antibodies and myeloperoxidase anti-neutrophil cytoplasmic antibodies.

Authors:  Hitoshi Watanabe; Wataru Kitagawa; Keisuke Suzuki; Masabumi Yoshino; Ryuhei Aoyama; Naoto Miura; Kazuhiro Nishikawa; Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2010-07-14       Impact factor: 2.801

8.  Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody.

Authors:  A Srivastava; G K Rao; P E Segal; M Shah; D Geetha
Journal:  Clin Rheumatol       Date:  2013-04-28       Impact factor: 2.980

9.  Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes.

Authors:  A Scott McCall; Gautam Bhave; Vadim Pedchenko; Jacob Hess; Meghan Free; Dustin J Little; Thomas P Baker; William F Pendergraft; Ronald J Falk; Stephen W Olson; Billy G Hudson
Journal:  J Am Soc Nephrol       Date:  2018-10-02       Impact factor: 10.121

10.  Uncommon structural motifs dominate the antigen binding site in human autoantibodies reactive with basement membrane collagen.

Authors:  Mary H Foster; Elizabeth S Buckley; Benny J Chen; Kwan-Ki Hwang; Amy G Clark
Journal:  Mol Immunol       Date:  2016-07-20       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.